Anaconda Pharma (the “Company”) is pleased to announce that it successfully secured its position as Leader of the CristaLead Program, a project recognized by a label from the ‘Pôle de Compétitivité’ Medicen Paris Region early in 2006 and now financed by the French Ministry of Industry.  In addition to Anaconda Pharma, the CristaLead Program gathers the knowledge and skills in chemo-informatics, chemistry and biology of private companies (Ariana Pharma and Medit) and public laboratories (Institut Pasteur, Paris and ICSN, CNRS). The goal of CristaLead is to develop novel antiviral compounds and screening and chemo-informatics technologies based on an innovative mechanism of action for drug discovery : protein-protein interactions. This program will yield to Anaconda Phama a minimum of €960,000 in non-repayable, non-dilutive grant financing over the coming 3 years. Dr. Marta Blumenfeld, Chief Executive comments; “This is great news for Anaconda Pharma and recognition of the first class, leading edge science being done at the company in the emerging filed of protein-protein interactions.  We look forward to working with our partners in this program to develop some truly innovative science over the coming 3 years”.
 
Anaconda Pharma is a privately held biopharmaceutical company incorporated in November 2003 and operating from lab space within the BioTop incubator at the Pasteur Institute campus in Paris, France.                 
Anaconda Pharma has developed a unique and proprietary platform for the discovery of small molecules that disrupt protein:protein interactions.  These represent a major new class of pharmaceutical targets which have been unexploited due to the difficulty of recognizing drug'able hot-spots on the surface of interacting proteins.
 
Anaconda Pharma’s unique technology platform includes:
- proprietary high definition crystallographic 3-D information on targets,
- proprietary cellular and in vitro screening assays, and
- patented lead molecules & series amenable to optimisation.
Anaconda Pharma is initially targeting condyloma, an HPV related-indication which represents the major HPV economic opportunity in industrialized countries.

Contact :

Anaconda Pharma
Pasteur BioTop
28 rue du Dr Roux
75724 Paris cedex 15, France
Tel :   33 (0)1 40 61 31 40
Fax :   33 (0)1 40 61 35 37
e-mail :